Sean Neary/Meaghan Smith
Finance Committee Unanimously Approves Froman to be U.S. Trade Representative
Finance Chairman: Mr. Froman is the Right Man to Lead USTR
WASHINGTON –Senate Finance Committee Chairman Max Baucus (D-Mont.) today led the committee to approve Mike Froman’s nomination to be U.S. Trade Representative by unanimous voice vote. The committee considered Froman’s nomination at a hearing on June 6th, during which Senator Baucus said the U.S. needs a strong trade representative on the job as Trans-Pacific Partnership negotiations continue and free trade agreement talks with the E.U. ramp up.
“Mr. Froman is the right man to lead USTR. He has the experience and the knowledge to help tackle America’s ambitious trade agenda,” Senator Baucus said. “I am glad he got such strong support in committee. He now deserves that same support in the full Senate. We need to quickly approve this nomination so Mr. Froman can hit the ground running and get to work.”
Froman is currently the assistant to the president and deputy national security advisor for international economics. He also chairs the Major Economics Forum on Energy and Climate, co-chairs the Transatlantic Economic Council and plays an active role in the G20 and G8 summits. Froman also served during the Clinton administration in various roles at the State Department, National Security Council and National Economic Council.
In addition to his government service, Froman was a senior fellow at the Council on Foreign Relations, a resident fellow at the German Marshall Fund and worked in the private sector. He received his A.B. from Princeton University, Ph.D. in international relations from Oxford University and a J.D. from Harvard Law School.
Next Article Previous Article
- Senate Finance Republicans: IRS Document Destruction Harmed Taxpayers
- Government Watchdog Says IRS Needs to Address Critical Safeguard Weaknesses
- Crapo Statement at Taiwan Tax Legislation Markup
- Pandemic Unemployment Fraud Estimates Double to $100-$135 Billion; Crapo, Smith Call for Action
- Fact Sheet: Democrats’ Drug Price-Setting Scheme Dismantles Medicare’s Promise, Undermines Seniors’ Health